Zobrazeno 1 - 10
of 24
pro vyhledávání: '"DMARDs (biologics)"'
Autor:
Paul Emery, Yoshiya Tanaka, Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, Cameron Helt, Josef S. Smolen
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitin
Externí odkaz:
https://doaj.org/article/e317c23630444373bfbf737a0dffda84
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kevin L. Winthrop, Clifton O. Bingham, Wendy J. Komocsar, John Bradley, Maher Issa, Rena Klar, Cynthia E. Kartman
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately
Externí odkaz:
https://doaj.org/article/fb4179395d57473eb50cfb25ed303174
Autor:
Josef S Smolen, Paul Emery, Scott D. Beattie, Terence Rooney, Yoshiya Tanaka, Cameron Helt, Tracy Cardillo, Douglas E Schlichting
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Background In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitinib and pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8886f607d3f1350c39c599c3e6cc129
http://link.springer.com/article/10.1186/s13075-020-02199-8
http://link.springer.com/article/10.1186/s13075-020-02199-8
Autor:
Cynthia E. Kartman, Maher Issa, Wendy J. Komocsar, Clifton O. Bingham, Rena Klar, John S. Bradley, Kevin L. Winthrop
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients with rheumatoid arthritis (RA). Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately to sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a05524af9ef13e287c326c6bd053037e
http://link.springer.com/article/10.1186/s13075-019-1883-1
http://link.springer.com/article/10.1186/s13075-019-1883-1
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-2 (2020)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitinib and pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614dc31e4524d1032070b8a3e3d3fa1c
http://link.springer.com/article/10.1186/s13075-020-02257-1
http://link.springer.com/article/10.1186/s13075-020-02257-1
Autor:
Terence Rooney, Yoshiya Tanaka, Peter C. Taylor, R Ortmann, Bruno Fautrel, Himanshu Patel, Li Xie, Edward C. Keystone, B Zhu, Maher Issa, Stephanie de Bono, Carol L. Gaich
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme.MethodsIn phase III RA-BEAM, patients were randomised 3:3:2 to placebo,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0373fe0cebe28e4aeb43850de870b2
http://ora.ox.ac.uk/objects/uuid:
http://ora.ox.ac.uk/objects/uuid:
Autor:
William L. Macias, Iain B. McInnes, Stephanie de Bono, Chadi Saifan, Giacomo Ruotolo, Douglas E Schlichting, L. Chen, Steven H. Zuckerman, Joel M. Kremer, Paul Emery, Peter C. Taylor, James D. Otvos, Margery A. Connelly, Jinglin Zhong, Sarah Witt, Monika Kurzawa, Terence Rooney
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesLipid profiles are altered by active disease in patients with rheumatoid arthritis (RA) and may be further modified by treatment with Janus kinase inhibitors and other disease-modifying antirheumatic drugs.MethodsLipid data were analysed fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0c39bb68a267c353954c5bf655b0db
https://eprints.gla.ac.uk/158340/1/158340.pdf
https://eprints.gla.ac.uk/158340/1/158340.pdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Scopus-Elsevier
The purpose of this study was to have an overview of the current approach to psoriatic arthritis (PsA) by a group of Italian rheumatologists.Rheumatologists from all around Italy were asked to participate in a survey to give their opinion on a number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::91af2af5760d9fac00114ea3fb07afa3
https://pubmed.ncbi.nlm.nih.gov/27462870
https://pubmed.ncbi.nlm.nih.gov/27462870